key: cord-0429955-w3paujjw
authors: Yorsaeng, R.; Vichaiwattana, P.; Klinfueng, S.; Wongsrisang, L.; Sudhinaraset, N.; Vongpunsawad, S.; Poovorawan, Y.
title: Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria)
date: 2021-09-03
journal: nan
DOI: 10.1101/2021.09.01.21262955
sha: e0823af6b99af949249f4fa21d48d20a7977df93
doc_id: 429955
cord_uid: w3paujjw

Limited COVID-19 vaccines in many countries have delayed mass-immunization. Although individuals fully vaccinated with Vaxzevria (AstraZeneca) have higher antibody levels than those with CoronaVac (Sinovac), heterologous prime-boost with CoronaVac-Vaxzevria yielded comparable antibody levels to two-dose Vaxzevria. Combination use of different available vaccines may be warranted in Thailand, which faces limited vaccine choice and supply.

weeks apart) and Vaxzevria (10-12 weeks apart) (4). Since then, limited vaccine availability Vaxzevria as second dose. 4 7 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We observed that the geometric mean antibody titer among the two-dose CoronaVac (797 U/mL; 95% CI: 598.7-1062) was comparable to that of vaccinees who received two- dose Vaxzevria (818 U/mL; 95% CI: 662.5-1010), which was not a significant difference A limitation in this study is that the immunoassay quantified all immunoglobulins in 7 1 the serum samples and did not distinguish between the short-term immunity conveyed by 7 2 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. may not be associated with protection. We were also unable to ascertain virus-specific 7 4 neutralizing antibodies nor quantify specific T-cell response. In retrospect, it would have 7 5 been ideal to solicit adverse events associated with heterologous vaccination from individuals 7 6 at the time of sample collection. Finally, the Roche assay used in this study may not have 7 7 accurately reflected the antibody measurement specific to the current SARS-CoV2 variants in 7 8 circulation.

The desire to maximize antibody response elicited from different SARS-CoV-2 vaccine inactivated and S-encoding vaccine prime-boost schedule.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2021. ; https://doi.org/10.1101/2021.09.01.21262955 doi: medRxiv preprint 2. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al.

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 6. Dyani L. Mix-and-match COVID vaccines: the case is growing, but questions remain. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2021. ; https://doi.org/10.1101/2021.09.01.21262955 doi: medRxiv preprint

Vaccines for 9

COVID-19: Where do we stand in 2021?

All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. University, and King Chulalongkorn Memorial Hospital. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted September 3, 2021. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted September 3, 2021. ; https://doi.org/10.1101/2021.09.01.21262955 doi: medRxiv preprint